
Opinion|Videos|July 10, 2024
Improvement in Management of Duchenne Muscular Dystrophy in Recent Years
Author(s)Emma Ciafaloni, MD
A neurologist discusses how recent approvals of therapies for Duchenne muscular dystrophy have improved patient outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following questions:
- How have these recent approvals improved the management of Duchenne muscular dystrophy (DMD)?
- Share your experience with recent approvals in DMD.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
CTAD Presentation Lays Insights Into Disappointing Phase 3 EVOKE Trial of GLP-1 Semaglutide in Alzheimer Disease
2
Additional Insights From the U.S. POINTER Study at CTAD 2025: Heather M. Snyder, PhD
3
New Clarity AD Analysis Reveal How Lecanemab Engages and Clears Neurotoxic Protofibrils in Alzheimer Disease
4
Merck’s Novel Antibody MK-2214 Receives FDA Fast-Track Designation Following Phase 1 Results
5



































